Articles by Cecilia Brown
Dr. Jänne reflects on the importance of World Lung Cancer Day, which is marked on August 1 annually.
The guideline panel additionally determined that guided-bronchoscopy sampling delivers a “superior safety profile."
FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 ...
Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall ...
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Dr. Liu weighs in on the CheckMate 816 data presented at the 2025 ASCO Annual Meeting.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Dr. Sen explains how her team identified targetable genes that define immune suppression in small cell lung cancer.
Stephen Liu, MD, shares his insights on the recent approval, the data behind it, and what the future may hold.
Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ...
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Sanjay Juneja, MD, was joined by lung cancer experts Dr. Liu, Dr. Das, and Dr. Singhi to discuss critical ASCO 2025 data.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.